Literature DB >> 24528128

Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden.

Justo Lorenzo Bermejo1, Eero Pukkala, Tom B Johannesen, Jan Sundquist, Kari Hemminki.   

Abstract

Survival after non-Hodgkin lymphoma (NHL) has increased thanks to improved treatment but NHL survivors have an increased risk of second neoplasms. The assessment of cancer risk patterns after NHL may help to quantify the late side-effects of therapy. Poisson regression was used to estimate relative risks (RRs) and absolute incidence rates for nine solid tumours based on a nationwide cohort of 60 901 NHL survivors from Finland, Norway and Sweden. Patients were diagnosed between 1980 and 2006 and developed 6815 s neoplasms. NHL patients showed an increased risk of each of the nine investigated cancer sites: prostate and pancreas (both RRs 1·28), breast (1·37), colorectum (1·48), urinary bladder (1·52), stomach and lung (both RRs 1·87), skin (melanoma 2·27) and kidney (2·56). The RRs showed a U-shaped relationship with time after NHL for all nine-second cancer types. NHL diagnosis early in life was a risk factor for the development of second cancers with the exception of melanoma, but a risk excess was even observed in patients diagnosed with NHL at age 80+ years. The present study provides accurate estimates on the adverse late effects of NHL therapy, which should guide the establishment of cancer prevention strategies in NHL survivors.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  absolute risks; non-Hodgkin lymphoma; population-based risk estimates; relative risks; second neoplasms

Mesh:

Year:  2013        PMID: 24528128     DOI: 10.1111/bjh.12684

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

Authors:  Niuscha Yaktapour; Frank Meiss; Justin Mastroianni; Thorsten Zenz; Hana Andrlova; Nimitha R Mathew; Rainer Claus; Barbara Hutter; Stefan Fröhling; Benedikt Brors; Dietmar Pfeifer; Milena Pantic; Ingrid Bartsch; Timo S Spehl; Philipp T Meyer; Justus Duyster; Katja Zirlik; Tilman Brummer; Robert Zeiser
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

2.  Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Authors:  C Casulo; B Day; K L Dawson; X Zhou; C R Flowers; C M Farber; J D Hainsworth; J R Cerhan; B K Link; A D Zelenetz; J W Friedberg
Journal:  Ann Oncol       Date:  2015-09-11       Impact factor: 32.976

3.  Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors.

Authors:  Priyanka A Pophali; Melissa C Larson; Cristine Allmer; Umar Farooq; Brian K Link; Matthew J Maurer; James R Cerhan; Carrie A Thompson
Journal:  J Cancer Surviv       Date:  2020-01-02       Impact factor: 4.442

4.  Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.

Authors:  Ajay Major; Derek E Smith; Debashis Ghosh; Rachel Rabinovitch; Manali Kamdar
Journal:  Cancer       Date:  2019-09-11       Impact factor: 6.921

Review 5.  Temporal trends in the risk of developing multiple primary cancers: a systematic review.

Authors:  Yuanzi Ye; Amanda L Neil; Karen E Wills; Alison J Venn
Journal:  BMC Cancer       Date:  2016-11-04       Impact factor: 4.430

6.  [A case report: an EML4-ALK positive lung adenocarcinoma diagnosed 
with lymphoma previously].

Authors:  Li Liu; Wei Heng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-02

7.  Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study.

Authors:  Joel Joelsson; Tove Wästerlid; Richard Rosenquist; Lasse Hjort Jakobsen; Tarec C El-Galaly; Karin E Smedby; Sandra Eloranta
Journal:  Blood Adv       Date:  2022-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.